Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

(2019) Antonis Fanouriakis et al.   ANNALS OF THE RHEUMATIC DISEASES

Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre

(2018) Rudra Prosad Goswami et al.   CLINICAL RHEUMATOLOGY

Cumulative Burden of Glucocorticoid-related Adverse Events in Patients with Systemic Lupus Erythematosus: Findings from a 12-year Longitudinal Study

(2017) Hung-Lin Chen et al.   JOURNAL OF RHEUMATOLOGY

From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenile-Onset Systemic Lupus Erythematosus

(2017) Lily S. H. Lim et al.   ARTHRITIS CARE & RESEARCH

Remission in systemic lupus erythematosus: durable remission is rare

(2016) Theresa R Wilhelm et al.   ANNALS OF THE RHEUMATIC DISEASES

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

(2016) Cindy Strehl et al.   ANNALS OF THE RHEUMATIC DISEASES

A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)

(2016) Ronald van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus

(2016) Michel W. P. Tsang-A-Sjoe et al.   RHEUMATOLOGY

Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period

(2016) Carmen V. Medina-Quiñones et al.   ARTHRITIS CARE & RESEARCH

Prolonged remission in Caucasian patients with SLE: prevalence and outcomes

(2015) Margherita Zen et al.   ANNALS OF THE RHEUMATIC DISEASES

The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort

(2014) Manuel F Ugarte-Gil et al.   ANNALS OF THE RHEUMATIC DISEASES

Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

(2014) Ian N Bruce et al.   ANNALS OF THE RHEUMATIC DISEASES

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force

(2014) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus

(2014) A. J. Steiman et al.   JOURNAL OF RHEUMATOLOGY

Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus

(2014) I. Ruiz-Arruza et al.   RHEUMATOLOGY

Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years

(2014) Chee-Seng Yee et al.   RHEUMATOLOGY

Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study)

(2012) Nathalie Costedoat-Chalumeau et al.   ANNALS OF THE RHEUMATIC DISEASES

Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis

(2012) George K Bertsias et al.   ANNALS OF THE RHEUMATIC DISEASES

An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA

(2010) D. A. Isenberg et al.   ANNALS OF THE RHEUMATIC DISEASES

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs

(2010) G. K. Bertsias et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis

(2010) Michael Walsh et al.   ARTHRITIS CARE & RESEARCH

Prednisone, Lupus Activity, and Permanent Organ Damage

(2009) M. THAMER et al.   JOURNAL OF RHEUMATOLOGY

The BILAG-2004 index is sensitive to change for assessment of SLE disease activity

(2009) Chee-Seng Yee et al.   RHEUMATOLOGY

Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial

(2008) T Pincus et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2‐year prospective study

(2008) C. C. Mok et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY